172 related articles for article (PubMed ID: 28611105)
1. The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks.
Bombarde O; Larminat F; Gomez D; Frit P; Racca C; Gomes B; Guilbaud N; Calsou P
Mol Cancer Ther; 2017 Oct; 16(10):2166-2177. PubMed ID: 28611105
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II.
Brel V; Annereau JP; Vispé S; Kruczynski A; Bailly C; Guilbaud N
Biochem Pharmacol; 2011 Dec; 82(12):1843-52. PubMed ID: 21924246
[TBL] [Abstract][Full Text] [Related]
3. F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system.
Barret JM; Kruczynski A; Vispé S; Annereau JP; Brel V; Guminski Y; Delcros JG; Lansiaux A; Guilbaud N; Imbert T; Bailly C
Cancer Res; 2008 Dec; 68(23):9845-53. PubMed ID: 19047165
[TBL] [Abstract][Full Text] [Related]
4. Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage.
Gentry AC; Pitts SL; Jablonsky MJ; Bailly C; Graves DE; Osheroff N
Biochemistry; 2011 Apr; 50(15):3240-9. PubMed ID: 21413765
[TBL] [Abstract][Full Text] [Related]
5. Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II.
Ballot C; Jendoubi M; Kluza J; Jonneaux A; Laine W; Formstecher P; Bailly C; Marchetti P
Apoptosis; 2012 Apr; 17(4):364-76. PubMed ID: 22127645
[TBL] [Abstract][Full Text] [Related]
6. Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy.
Ma Y; North BJ; Shu J
Mol Biol Rep; 2021 Sep; 48(9):6589-6601. PubMed ID: 34476738
[TBL] [Abstract][Full Text] [Related]
7. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
[TBL] [Abstract][Full Text] [Related]
8. Effect of TDP2 on the Level of TOP2-DNA Complexes and SUMOylated TOP2-DNA Complexes.
Lee KC; Swan RL; Sondka Z; Padget K; Cowell IG; Austin CA
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011940
[TBL] [Abstract][Full Text] [Related]
9. An integrated Drosophila model system reveals unique properties for F14512, a novel polyamine-containing anticancer drug that targets topoisomerase II.
Chelouah S; Monod-Wissler C; Bailly C; Barret JM; Guilbaud N; Vispé S; Käs E
PLoS One; 2011; 6(8):e23597. PubMed ID: 21853156
[TBL] [Abstract][Full Text] [Related]
10. Suppressing proteasome mediated processing of topoisomerase II DNA-protein complexes preserves genome integrity.
Sciascia N; Wu W; Zong D; Sun Y; Wong N; John S; Wangsa D; Ried T; Bunting SF; Pommier Y; Nussenzweig A
Elife; 2020 Feb; 9():. PubMed ID: 32057297
[TBL] [Abstract][Full Text] [Related]
11. F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer.
Thibault B; Clement E; Zorza G; Meignan S; Delord JP; Couderc B; Bailly C; Narducci F; Vandenberghe I; Kruczynski A; Guilbaud N; Ferré P; Annereau JP
Cancer Lett; 2016 Jan; 370(1):10-8. PubMed ID: 26404751
[TBL] [Abstract][Full Text] [Related]
12. Proteolytic degradation of topoisomerase II (Top2) enables the processing of Top2·DNA and Top2·RNA covalent complexes by tyrosyl-DNA-phosphodiesterase 2 (TDP2).
Gao R; Schellenberg MJ; Huang SY; Abdelmalak M; Marchand C; Nitiss KC; Nitiss JL; Williams RS; Pommier Y
J Biol Chem; 2014 Jun; 289(26):17960-9. PubMed ID: 24808172
[TBL] [Abstract][Full Text] [Related]
13. Repair of trapped topoisomerase II covalent cleavage complexes: Novel proteasome-independent mechanisms.
Tsuda M; Kitamasu K; Hosokawa S; Nakano T; Ide H
Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):170-184. PubMed ID: 31608820
[TBL] [Abstract][Full Text] [Related]
14. Replication-dependent and transcription-dependent mechanisms of DNA double-strand break induction by the topoisomerase 2-targeting drug etoposide.
Tammaro M; Barr P; Ricci B; Yan H
PLoS One; 2013; 8(11):e79202. PubMed ID: 24244448
[TBL] [Abstract][Full Text] [Related]
15. Depletion of tyrosyl DNA phosphodiesterase 2 activity enhances etoposide-mediated double-strand break formation and cell killing.
Kont YS; Dutta A; Mallisetty A; Mathew J; Minas T; Kraus C; Dhopeshwarkar P; Kallakury B; Mitra S; Üren A; Adhikari S
DNA Repair (Amst); 2016 Jul; 43():38-47. PubMed ID: 27235629
[TBL] [Abstract][Full Text] [Related]
16. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.
Maede Y; Shimizu H; Fukushima T; Kogame T; Nakamura T; Miki T; Takeda S; Pommier Y; Murai J
Mol Cancer Ther; 2014 Jan; 13(1):214-20. PubMed ID: 24130054
[TBL] [Abstract][Full Text] [Related]
17. An optimized polyamine moiety boosts the potency of human type II topoisomerase poisons as quantified by comparative analysis centered on the clinical candidate F14512.
Palermo G; Minniti E; Greco ML; Riccardi L; Simoni E; Convertino M; Marchetti C; Rosini M; Sissi C; Minarini A; De Vivo M
Chem Commun (Camb); 2015 Oct; 51(76):14310-3. PubMed ID: 26234198
[TBL] [Abstract][Full Text] [Related]
18. MRN, CtIP, and BRCA1 mediate repair of topoisomerase II-DNA adducts.
Aparicio T; Baer R; Gottesman M; Gautier J
J Cell Biol; 2016 Feb; 212(4):399-408. PubMed ID: 26880199
[TBL] [Abstract][Full Text] [Related]
19. Genome-Wide CRISPR Screens Reveal ZATT as a Synthetic Lethal Target of TOP2-Poison Etoposide That Can Act in a TDP2-Independent Pathway.
Park JM; Zhang H; Nie L; Wang C; Huang M; Feng X; Tang M; Chen Z; Xiong Y; Lee N; Li S; Yin L; Hart T; Chen J
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047518
[TBL] [Abstract][Full Text] [Related]
20. The polyphenolic ellagitannin vescalagin acts as a preferential catalytic inhibitor of the α isoform of human DNA topoisomerase II.
Auzanneau C; Montaudon D; Jacquet R; Puyo S; Pouységu L; Deffieux D; Elkaoukabi-Chaibi A; De Giorgi F; Ichas F; Quideau S; Pourquier P
Mol Pharmacol; 2012 Jul; 82(1):134-41. PubMed ID: 22528119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
